Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
EOM's structural DNA reveals a CMS that learned hard lessons from OCM's near-universal failure to generate net savings and is now engineering accountability into the model's foundation rather than treating it as optional. Three design choices define this shift.
Cancer-type-specific benchmarking is the most consequential architectural decision. OCM's aggregated benchmarking obscured enormous variation in drug costs and care intensity across cancer types, allowing practices with favorable case mix to generate savings without genuine care transformation. EOM's disaggregation by seven tumor types — high-risk breast, lung, chronic leukemia, small intestine/colorectal, lymphoma, multiple myeloma, and high-risk prostate — eliminates this arbitrage. Practices can no longer cross-subsidize high-cost cancer management with savings from lower-acuity patients. This is structurally sound but operationally punishing: a practice with a dominant multiple myeloma population now bears the full benchmark exposure for one of oncology's most expensive treatment pathways, where novel immunotherapy regimens routinely exceed $300,000 per episode.
Mandatory downside risk from day one is a hard break from OCM's ramp structure. OCM's one-sided payment period allowed practices to collect performance payments without repayment exposure early in the model, which structurally inflated apparent participation value and delayed behavioral change. EOM imposes downside risk across the full participation period for both cohorts. This filters the participant pool toward financially sophisticated, operationally mature practices — 23 PGPs as of the current participant list — but creates an immediate cash-flow governance requirement that many smaller independent oncology groups cannot meet without capital reserves or an institutional backer.
The Cohort 2 compression creates a structural disadvantage. Cohort 1 launched July 1, 2023, with a seven-year runway ending June 30, 2030. Cohort 2 launched July 1, 2025, with only five years to that same end date. Both cohorts end simultaneously. This means Cohort 2 participants have 29% less time to amortize infrastructure investment, achieve learning-curve cost reductions, and generate cumulative performance-based payments. The IRR calculation for Cohort 2 participation is materially worse than Cohort 1 under identical operating assumptions. CMS has not, based on available source material, disclosed whether Cohort 2 benchmarks or quality targets were adjusted to account for this compressed timeline.
The new Substance Access Beneficiary Engagement Incentive (BEI) launching in Performance Period 6 signals CMS is actively expanding the model's care transformation scope mid-cycle. Adding a substance access BEI into an already operationally complex model creates compliance overhead and suggests CMS views EOM as a living laboratory rather than a stable contractual environment. Practices should expect further mid-model amendments.
MEOS payments are the floor, not the ceiling, of the financial case.
At $110 PBPM for standard Medicare beneficiaries and $140 PBPM for dually eligible individuals, MEOS payments are the model's guaranteed revenue stream. A practice managing 100 active EOM beneficiaries per month generates $11,000–$14,000 monthly ($132,000–$168,000 annually) in MEOS revenue before any performance-based payment or downside exposure. That figure must cover the incremental cost of eight mandatory participant redesign activities, including 24/7 clinician access (which typically requires either on-call stipends or a dedicated triage infrastructure), patient navigation FTEs, ePRO platform licensing, and HRSN screening workflows.
Rough break-even framework: A minimally staffed care transformation infrastructure — one navigator, partial care coordinator time, ePRO platform, and 24/7 clinical coverage allocation — conservatively costs $150,000–$250,000 annually in incremental expense. At $110 PBPM, a practice needs approximately 115–190 active EOM beneficiaries monthly to cover infrastructure cost from MEOS alone, before accounting for performance-based payment upside or downside exposure. Practices below this volume threshold are structurally dependent on performance-based payments to achieve positive ROI, which introduces income volatility incompatible with stable program operations.
Performance-based payment scenarios (illustrative, based on model structure):
Best case: A high-volume practice (200+ active beneficiaries/month, 1,400+ episodes/year) with strong care management achieving 5–7% spending reduction below benchmark across two or three cancer types generates MEOS revenue of $264,000–$336,000 annually plus performance-based payments potentially in the $500,000–$1M+ range depending on episode volume and benchmark design. Net positive program economics are achievable but require operational excellence.
Expected case: A mid-size practice (100–150 beneficiaries/month) achieving modest savings on some cancer types while breaking even on others generates MEOS revenue of $132,000–$198,000 and modest or flat performance-based payments, covering incremental costs with limited margin. Participation value is primarily strategic (data infrastructure, quality culture) rather than financial.
Worst case: A practice with high multiple myeloma or lung cancer volume that experiences even one high-cost outlier quarter — a CAR-T eligible patient, a treatment-related hospitalization surge — may face repayment obligations that wipe out multiple months of MEOS revenue. Downside exposure is uncapped by episode design mechanics; practices without reinsurance arrangements or institutional backstop face real financial risk.
Cash flow timing is a critical operational risk. MEOS payments flow monthly, providing predictable cash. Performance-based payments and repayment obligations are determined through reconciliation after each performance period, creating a lag of potentially 6–12 months between care delivery and financial settlement. Practices must maintain operating reserves sufficient to absorb potential repayment obligations without disrupting clinical operations.
Large, vertically integrated oncology groups and health system-employed practices are structurally advantaged. They bring existing care management infrastructure, EHR interoperability, employed navigator capacity, and institutional capital to absorb downside risk. The 23-participant Cohort 1 list reflects this — EOM has not democratized participation; it has concentrated it among operationally sophisticated organizations.
Independent community oncology practices face a genuine viability challenge. The eight mandatory participant redesign activities represent fixed-cost infrastructure that independent practices must build largely from scratch. The MIPS payment adjustment exception for MEOS payments is a meaningful carve-out but doesn't address the capital access problem. Private equity-backed oncology platforms are positioned to use EOM participation as a consolidation catalyst — offering infrastructure-sharing and downside risk pooling as acquisition rationale to independent practices who cannot meet EOM's operational requirements alone.
BlueCross BlueShield of South Carolina as the sole participating commercial payer is a notable data point. After two model years (and now a second cohort), EOM has attracted exactly one commercial payer partner. This signals either that commercial payers find the model's episode design and financial mechanics unattractive at current terms, or that CMS has not aggressively pursued payer alignment. Health systems with active Medicare Advantage contracts should note that EOM's Medicare FFS episode structure does not automatically extend to MA lives — coordination between EOM participation and MA contract terms requires explicit negotiation.
Interaction with MSSP: Oncology practices whose patients are attributed to MSSP ACOs face layered accountability — the ACO bears total cost accountability for the same patients whose chemotherapy episodes are attributed to EOM. This overlap requires careful coordination between PGP leadership and ACO financial teams to avoid conflicting incentives around referral patterns, site-of-care decisions, and post-acute utilization.
Physician perspective: EOM's mandatory downside risk represents a structural change in risk tolerance requirements for oncologist participation. The ePRO collection and HRSN screening requirements add documentation burden at the point of care unless practices have invested in integrated technology workflows. The clinical upside — cancer-type-specific benchmarks that reward genuine care innovation, access to CMS performance data — is real but requires a practice culture oriented toward continuous quality improvement rather than volume optimization.
Health system perspective: EOM is a strategic asset for health systems seeking to anchor oncology service line economics in value-based contracts. The model provides a structured framework for demonstrating population health management capability in oncology — valuable for MA contract negotiations and ACO positioning. Systems should evaluate EOM participation as part of a portfolio strategy, not in isolation.
Hospital perspective: Hospitals are not direct EOM participants — PGPs hold the participation agreement. But hospital-affiliated oncology practices generate substantial downstream inpatient and outpatient revenue that EOM's incentives directly target. EOM rewards avoidance of unnecessary hospital visits and improved end-of-life care planning, both of which can reduce hospital admissions. Hospital CFOs should model the inpatient revenue impact of EOM-driven care transformation before encouraging affiliated practices to participate aggressively.
Payer/MA plan perspective: With one commercial payer participant after two-plus years, EOM's commercial extension has not scaled. MA plans with oncology-heavy member populations should monitor EOM cost and quality performance data — CMS publicly released first reconciliation performance data on August 25, 2025 — as a benchmark for their own oncology episode program designs. The model's cancer-type-specific benchmarking methodology and ePRO collection requirements are direct inputs to commercial VBC oncology program design.
ValuesEdge analysis is prepared for institutional decision-making. Model terms, participation requirements, and payment rates are subject to CMS amendment. Verify current program details at CMS.gov before making participation or contracting decisions.